Company profile for Summit Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We’re developing new mechanism antibiotics to become the new standards of care. We have a clear strategy: through new science and philosophy, we are creating new opportunities to become the standard of care for serious infectious diseases. Our proprietary Discuva Platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. To date, the Discuva Platform has developed two new tar...
We’re developing new mechanism antibiotics to become the new standards of care. We have a clear strategy: through new science and philosophy, we are creating new opportunities to become the standard of care for serious infectious diseases. Our proprietary Discuva Platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. To date, the Discuva Platform has developed two new targets for gonorrhoea, an ESKAPE programme and undisclosed programmes with Roche.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2882 Sand Hill Road Suite 106 Menlo Park CA, 94025
Telephone
Telephone
+44 (0)1235 443 939
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251205119192/en/Summit-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

BUSINESSWIRE
05 Dec 2025

https://www.prnewswire.com/news-releases/ivonescimab-harmoni-a-study-final-os-analysis-results-presented-at-sitc-2025-with-os-hr0-74--302608764.html

PR NEWSWIRE
07 Nov 2025

https://www.businesswire.com/news/home/20251031005548/en/Overall-Survival-Data-from-HARMONi-A-Featuring-Ivonescimab-in-Combination-with-Chemotherapy-vs.-Chemotherapy-in-2L-Treatment-of-Patients-with-EGFRm-NSCLC-in-China-to-be-Showcased-at-SITC-2025

BUSINESSWIRE
31 Oct 2025

https://www.businesswire.com/news/home/20251022041844/en/Summit-Therapeutics-Raises-%24500-Million-in-Private-Placement

BUSINESS WIRE
22 Oct 2025

https://www.biospace.com/business/summit-eyes-2025-fda-application-for-ivonescimab-despite-overall-survival-miss

BIOSPACE
21 Oct 2025

https://www.businesswire.com/news/home/20251020040157/en/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2025

BUSINESSWIRE
20 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty